The study also demonstrated that TP53/EGFR co-mutations had lower response rates and shorter PFS than TP53 wild type in NSCLC with EGFR-TKI therapy; TP53 status did not impact the probability of developing CNS metastases either from diagnosis or from the start of TKIs at 5 years; however, this study included stages I–III (22). Here, EGFR is linked to non-small cell lung carcinoma.